The preselection based on age and family history for testing in genetics is likely to mean that the rate of BRCA1 pathogenic variants in metaplastic breast cancer is about 10-fold less based on the detection rates in all breast cancers tested. This evidence concerns the gene BRCA1 and breast cancer.